Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ari Zimran

Showing results (141-150 of 238) with videos related to

Pageof 24
Sort By:
Blood Cells, Molecules & Diseases|November 4, 2011
Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from JerusalemDeborah Elstein, Gheona Altarescu, Hannah Maayan, et al.
International Journal of Molecular Sciences|July 24, 2021
Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic FormulationsTama Dinur, Ulrike Grittner, Shoshana Revel-Vilk, et al.
Molecular Genetics and Metabolism|August 31, 2017
Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trialsDeborah Elstein, Björn Mellgard, Quinn Dinh, et al.
Calcified Tissue International|November 8, 2014
Gaucher disease and bone manifestationsGemma Marcucci, Ari Zimran, Bruno Bembi, et al.
JAMA|September 20, 2007
Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseasesShachar Zuckerman, Amnon Lahad, Amir Shmueli, et al.
Internal Medicine Journal|September 13, 2022
Rapid velaglucerase alfa infusion for Gaucher disease: 5-year dataMichal Becker-Cohen, Jeff Szer, Naama Arbel, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 29, 2005
A comprehensive assessment of renal function in patients with Gaucher diseaseRachel Becker-Cohen, Deborah Elstein, Ayala Abrahamov, et al.
Molecular Genetics and Metabolism Reports|January 13, 2018
Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome SurveyIda Vanessa D Schwartz, Özlem Göker-Alpan, Priya S Kishnani, et al.
Rheumatology International|March 5, 2008
Molecular aspects of osteopathy in type 1 Gaucher disease: correlation between genetics and bone densityEfrat Arnheim, Gaya Chicco, Mici Phillips, et al.
Journal of Inherited Metabolic Disease|September 22, 2025
Effect of Exposure to Enzyme Replacement Therapy on Bone Mineral Density in Children With Gaucher DiseaseShoshana Revel-Vilk, Maayan Tiomkin, Dafna Frydman, et al.
Pageof 24

Showing results (141-150 of 238) with videos related to

Sort By:
Pageof 24
Blood Cells, Molecules & Diseases|November 4, 2011
Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from JerusalemDeborah Elstein, Gheona Altarescu, Hannah Maayan, et al.
International Journal of Molecular Sciences|July 24, 2021
Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic FormulationsTama Dinur, Ulrike Grittner, Shoshana Revel-Vilk, et al.
Molecular Genetics and Metabolism|August 31, 2017
Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trialsDeborah Elstein, Björn Mellgard, Quinn Dinh, et al.
Calcified Tissue International|November 8, 2014
Gaucher disease and bone manifestationsGemma Marcucci, Ari Zimran, Bruno Bembi, et al.
JAMA|September 20, 2007
Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseasesShachar Zuckerman, Amnon Lahad, Amir Shmueli, et al.
Internal Medicine Journal|September 13, 2022
Rapid velaglucerase alfa infusion for Gaucher disease: 5-year dataMichal Becker-Cohen, Jeff Szer, Naama Arbel, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 29, 2005
A comprehensive assessment of renal function in patients with Gaucher diseaseRachel Becker-Cohen, Deborah Elstein, Ayala Abrahamov, et al.
Molecular Genetics and Metabolism Reports|January 13, 2018
Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome SurveyIda Vanessa D Schwartz, Özlem Göker-Alpan, Priya S Kishnani, et al.
Rheumatology International|March 5, 2008
Molecular aspects of osteopathy in type 1 Gaucher disease: correlation between genetics and bone densityEfrat Arnheim, Gaya Chicco, Mici Phillips, et al.
Journal of Inherited Metabolic Disease|September 22, 2025
Effect of Exposure to Enzyme Replacement Therapy on Bone Mineral Density in Children With Gaucher DiseaseShoshana Revel-Vilk, Maayan Tiomkin, Dafna Frydman, et al.
Pageof 24